Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Starpharma Holdings Ltd

Healthcare AU SPL

0.09AUD
-0.002(2.17%)

Last update at 2025-07-04T04:48:00Z

Day Range

0.090.09
LowHigh

52 Week Range

0.080.13
LowHigh

Fundamentals

  • Previous Close 0.09
  • Market Cap37.64M
  • Volume171787
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.23700M
  • Revenue TTM4.16M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM -5.74800M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -15.63800M -16.15400M -19.73200M -14.67800M -14.25400M
Minority interest - - - - -
Net income -15.63800M -16.15400M -19.73200M -14.67800M -12.88700M
Selling general administrative 3.77M 3.29M 4.02M 2.67M 2.50M
Selling and marketing expenses - - - - -
Gross profit 1.82M 1.91M 1.01M 5.14M 1.40M
Reconciled depreciation 1.19M 1.08M 0.93M 0.91M 0.30M
Ebit -18.23600M -17.71200M -22.35500M -16.67100M -15.62100M
Ebitda -17.04200M -16.63400M -21.42100M -15.76000M -15.32300M
Depreciation and amortization 1.19M 1.08M 0.93M 0.91M 0.30M
Non operating income net other - - - - -
Operating income -15.77300M -16.15400M -19.73200M -14.67800M -15.62100M
Other operating expenses 19.85M 21.32M 23.22M 21.79M 17.27M
Interest expense - 0.22M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 1.27M 0.22M 0.35M 0.52M 1.06M
Net interest income 1.27M 0.22M 0.35M 0.52M 1.06M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.46300M -1.29500M -1.28700M -1.43400M -1.36700M
Total revenue 2.94M 4.68M 1.80M 6.03M 1.65M
Total operating expenses 20.05M 19.62M 23.36M 21.81M 17.02M
Cost of revenue 1.12M 2.78M 0.79M 0.89M 0.25M
Total other income expense net 0.14M 0.26M 1.34M 0.56M 1.37M
Discontinued operations - - - - -
Net income from continuing ops -15.63800M -16.15400M -19.73200M -14.67800M -14.25400M
Net income applicable to common shares -15.63800M -16.15400M -19.73200M -14.67800M -14.25400M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 36.81M 52.09M 66.17M 73.24M 39.08M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.81M 0.93M 0.08M 0.10M 0.04M
Total liab 8.70M 17.27M 17.78M 10.94M 7.75M
Total stockholder equity 28.12M 34.81M 48.39M 62.30M 31.33M
Deferred long term liab - - - - -
Other current liab 2.34M 2.33M 2.31M 2.61M 1.26M
Common stock 240.75M 240.72M 240.67M 240.63M 193.66M
Capital stock - 240.72M 240.67M 240.63M 193.66M
Retained earnings -242.36400M -234.19900M -218.56100M -202.40700M -182.67500M
Other liab - 0.05M 0.06M 0.03M 0.09M
Good will - - - - -
Other assets 0.00000M - - - -
Cash 23.36M 35.18M 49.92M 60.50M 30.05M
Cash and equivalents - 33.52M 45.79M 57.30M 25.98M
Total current liabilities 6.66M 14.47M 10.23M 10.43M 6.70M
Current deferred revenue 0.03M 0.00300M 0.47M 0.41M 0.44M
Net debt -19.83200M -26.90800M -41.72900M -59.33300M -28.48000M
Short term debt 1.57M 5.52M 0.69M 0.69M 0.60M
Short long term debt - 4.78M - - -
Short long term debt total 3.53M 8.27M 8.19M 1.17M 1.57M
Other stockholder equity - -6.51600M -22.10800M -38.22300M -10.98600M
Property plant equipment - 4.96M 5.52M 2.48M 2.40M
Total current assets 32.92M 47.12M 60.66M 70.75M 36.68M
Long term investments - - - - -
Net tangible assets - 34.81M 48.39M 62.30M 31.33M
Short term investments - - - - -
Net receivables 6.34M 8.23M 7.84M 8.44M 6.09M
Long term debt - 0.00000M 4.00M - -
Inventory 2.41M 2.77M 2.82M 1.72M 0.49M
Accounts payable 2.73M 6.62M 6.76M 6.71M 4.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 29.73M 28.30M 26.29M 24.08M 20.34M
Additional paid in capital - - - - -
Common stock total equity - - - - 193.66M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -4.96400M -5.51700M -2.48300M -2.40200M
Deferred long term asset charges - - - - -
Non current assets total 3.90M 4.96M 5.52M 2.48M 2.40M
Capital lease obligations - 3.49M 4.19M 1.17M 1.57M
Long term debt total - 2.75M 7.49M 0.47M 0.97M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -0.08900M -0.61000M -0.83600M -0.24600M -0.12500M
Change to liabilities - -0.54700M 0.34M 2.91M -0.43600M
Total cashflows from investing activities - -0.61000M -0.83600M -0.24600M -0.12500M
Net borrowings - -0.69500M 3.23M -0.62800M -0.58400M
Total cash from financing activities -4.74700M -0.69500M 3.23M 46.30M -0.58400M
Change to operating activities - 0.71M -0.00900M 0.14M 0.17M
Net income -8.16500M -15.63800M -16.15400M -19.73200M -14.67800M
Change in cash -11.82000M -14.73800M -10.58200M 30.45M -11.19700M
Begin period cash flow 35.18M 49.92M 60.50M 30.05M 41.25M
End period cash flow 23.36M 35.18M 49.92M 60.50M 30.05M
Total cash from operating activities -6.97700M -13.53300M -13.16200M -14.80800M -10.77600M
Issuance of capital stock - - - 48.86M -
Depreciation 1.11M 1.19M 1.08M 0.94M 0.91M
Other cashflows from investing activities - 0.01M 0.00100M 0.00000M 0.00000M
Dividends paid - - - 46.30M -
Change to inventory 0.36M 0.05M -1.10300M -1.22700M -0.09500M
Change to account receivables 2.06M -1.25700M 0.63M -2.36900M 0.03M
Sale purchase of stock - - 0.00000M -1.93100M -1.93100M
Other cashflows from financing activities -0.74500M -0.69500M -0.77200M -0.62800M -0.58400M
Change to netincome - 1.95M 2.05M 4.54M 3.32M
Capital expenditures 0.09M 0.62M 0.84M 0.25M 0.12M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.40000M -1.04200M -0.14000M -0.55100M -0.32500M
Stock based compensation 1.47M 2.06M 2.25M 3.74M 3.60M
Other non cash items 0.07M 5.63M 4.40M 7.07M 5.65M
Free cash flow -7.06600M -14.15400M -13.99900M -15.05400M -10.90100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SPL
Starpharma Holdings Ltd		 -0.002 2.17% 0.09 - 312.50 9.05 1.64 6.80 -9.4943
CSL
CSL Ltd		 1.50 0.62% 242.50 28.55 32.05 7.64 4.03 5.80 18.01
TLX
Telix Pharmaceuticals Ltd		 0.40 1.67% 24.35 177.75 56.82 10.64 14.57 10.40 88.05
MSB
Mesoblast Ltd		 0.01 0.93% 1.63 - 454.55 369.57 2.90 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 0.20 1.41% 14.40 12.99 78.12 8.25 4.61 7.03 8.53

Reports Covered

Stock Research & News

View All

Profile

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; SPL7013 for vaginal gel; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Starpharma Holdings Ltd

4-6 Southampton Crescent, Abbotsford, VIC, Australia, 3067

Key Executives

Name Title Year Born
Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), GAICD, MBA CEO, MD & Exec. Director 1963
Mr. Nigel J. Baade B.Com, Grad. Dip., CPA CFO & Company Sec. NA
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.